Quality of Covaxin was never waived, says Grand Pharma after risk evaluation
World Health Organization (WHO) on Saturday stop show of Bharat Biotech’s COVID Vaccine, Covaxin, to allow Manufacturer to upgrade facilities and address deficiencies found during inspection last Month.
A statement issued by the World Health Organization stated that the suspension was in respond to results of it’s a post EUL (Emergency use authorization), which took place from 14 to 22 March 2022, and need To make process and facility upgrades to address recently identified Good Manufacturing Practices (GMP)good manufacturing practice) Shortcomings.
While there will be a break in supply of Covaccin risk The evaluation so far does not indicate a change in The risk- Interest rate according to the World Health Organization, adding that available The data indicates that the vaccine is effective and there is no safety Anxiety exists.
‘You will meet the standards’
In a statement issued on On April 1, Bharat Biotech said it is fully committed to implementing facility improvements and upgrades ensure that production of Covaxin meets everyone global regulatory requirements.
“in order to millions who They obtained Covaxin, vaccine certificates issued are still valid as there is no effect on efficacy and safety of Vaccine,” the company said. He – she added As a vaccine manufacturer safety is the primary consideration for No vaccine, therefore safety The efficacy will continue of fundamental importance.
Announcing a temporary slowdown down of cofaxine production for The company said that the facilities for The next period will focus the company on hanging attachment maintenanceprocess and facility improvement activities.
while the company on On Sunday he said he didn’t have anything add In the previous statement, he said the update was due as all existing facilities have been redirected for Industry of cofaxine, with Continuous production during past yearto meet public health emergency of COVID-19.
“Very sophisticated equipment which was required To reinforce the rigor of the process has not been available during the COVID-19 pandemic. Quality must be emphasized of Covaxin was never compromised in time,” the company noted.
He further explained that during the last WHO post Inspection of Emergency Use List (EUL) Procedures, Bharat Biotech . Approved with World Health Organization team on Domain of chart improvement Activities indicated that it will be implemented as soon my work.
The company was also We are pleased to learn from the World Health Organization, that the necessary improvement work Does not indicate change in The risk- interest rate (for Covaxin) and data, available To the World Health Organization, indicates that the vaccine is effective and not safety The anxiety is there.”
Bharat Biotechnology explained that this risk Evaluation by the World Health Organization on the supply of hundreds of millions of doses of Covaxin worldwide, during which the product demonstrated excellence safety and the event file in Detailed and comprehensive post Marketing control activities. by company more of a million doses of Covaxin has been entered into clinical trial mode, where safety of Topics are actively documented.
(with input from PTI)
.
